Knoop C, Dumonceaux M, Rondelet B, Estenne M
Unité de transplantation cardiaque et pulmonaire, service de pneumologie, hôpital Erasme, 808, route de Lennik, 1070 Bruxelles, Belgique.
Rev Mal Respir. 2010 Apr;27(4):365-82. doi: 10.1016/j.rmr.2010.02.009. Epub 2010 Mar 25.
In 2009 lung transplantation is a valuable therapeutic option for a number of patients suffering from end-stage pulmonary diseases. Lung transplantation frequently offers a major improvement in quality of life; however, long-term survival is often limited by the development of the bronchiolitis obliterans syndrome, which is the equivalent of a chronic pulmonary graft rejection. As the bronchiolitis obliterans syndrome is the commonest cause of death in the medium- and long-terms, all patients receive intense immunosuppressive treatment in order to prevent or stabilize this complication. This treatment induces a number of potentially severe complications including metabolic complications, infections and malignancies. The most frequent metabolic complications are arterial hypertension, chronic renal insufficiency, hyperlipidaemia, diabetes and osteoporosis. Bacterial, viral and fungal infections are the second commonest cause of mortality. They are to be considered as medical emergencies and require urgent assessment and targeted therapy after microbiological specimens have been obtained. They should not under any circumstances be treated empirically and it should also be kept in mind that the lung transplant recipient may present several concomitant infections. The most frequent malignancies are post-transplant lymphoproliferative disorders, cutaneous neoplasias, Kaposi's sarcoma, some peculiar types of head and neck neoplasia, bronchogenic carcinomas and cancers of the digestive tract. The respiratory physician should recognize the symptoms and signs of specific complications induced by the immunosuppressive regimen and the goal of this report is to give a general overview of the most frequently encountered complications. Their assessment and treatment, though, will most often require the input of other specialists and a multidisciplinary approach.
2009年,肺移植对于许多终末期肺病患者而言是一种有价值的治疗选择。肺移植常常能显著改善生活质量;然而,长期存活往往受到闭塞性细支气管炎综合征发展的限制,该综合征相当于慢性肺移植排斥反应。由于闭塞性细支气管炎综合征是中长期最常见的死亡原因,所有患者都接受强化免疫抑制治疗,以预防或稳定这种并发症。这种治疗会引发一些潜在的严重并发症,包括代谢并发症、感染和恶性肿瘤。最常见的代谢并发症是动脉高血压、慢性肾功能不全、高脂血症、糖尿病和骨质疏松症。细菌、病毒和真菌感染是第二常见的死亡原因。它们应被视为医疗急症,在获取微生物标本后需要紧急评估和针对性治疗。在任何情况下都不应进行经验性治疗,还应牢记肺移植受者可能同时存在多种感染。最常见的恶性肿瘤是移植后淋巴细胞增生性疾病、皮肤肿瘤、卡波西肉瘤、一些特殊类型的头颈部肿瘤、支气管癌和消化道癌。呼吸内科医生应认识到免疫抑制方案引发的特定并发症的症状和体征,本报告的目的是对最常遇到的并发症进行总体概述。不过,对它们的评估和治疗通常需要其他专科医生的参与以及多学科方法。